Melanoma Patients' Preferences for Adjuvant Therapy
Author Information
Author(s): Toni Maria Janke, Laura Moysig, Christine Blome, Katharina C. Kähler
Primary Institution: Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
Hypothesis
What are personal motives for tolerating or rejecting adjuvant therapy and its side effects?
Conclusion
Patients in our study indicate high willingness to undergo adjuvant therapy, even when facing toxicity.
Supporting Evidence
- Patients expressed a willingness to tolerate side effects for the chance of preventing cancer recurrence.
- Participants emphasized the importance of maintaining quality of life while undergoing treatment.
- Many patients preferred treatment options that would minimally disrupt their daily lives.
Takeaway
Patients with melanoma are willing to try treatments even if they might make them feel sick, because they hope it will help them live longer.
Methodology
Semi-structured interviews were conducted with a subsample of patients to investigate the underlying reasons for treatment decisions.
Potential Biases
The study may be influenced by recall bias as participants reflected on their past experiences with cancer.
Limitations
Participants were recruited at a single study center, which may not represent the broader patient population.
Participant Demographics
Mean age of participants was 55.5 years, with 12 females and 5 males.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website